With over 39 years of photobiomodulation experience, James Carroll is a recognised authority in the field of Photobiomodulation (PBM). He founded an industry-leading company, THOR Photomedicine, collaborates with many of the foremost PBM academics, co-authored 38 PBM papers, and contributed chapters to five PBM books. He is a recognised authority on PBM dose, dose-rate effects, and the measurement and reporting of parameters, and has collaborated with over 50 academic institutions worldwide. His name and/or products have appeared in 165 academic papers.

PROFESSIONAL APPOINTMENTS:
Fellow, The Royal Society of Medicine (2009-present)
Editorial Board Member, Photobiomodulation, Photomedicine and Laser Surgery (2008-2013)
Board Member, World Association for Photobiomodulation Therapy (2000-2004; 2018-present)
Board Member, North American Association for Laser Therapy (2002-2006)
Co-Chair, Biomedical Optics Society Conference on PBM Mechanisms (2009-2024)

NOTABLE SPEAKING ENGAGEMENTS:
Congressional briefing on Photobiomodulation as a potential solution to the opioid crisis
White House briefing on Photobiomodulation and pain management
United Nations Global Health Impact Forum presentation on PBM treatment of dry age-related macular degeneration

AWARDS AND RECOGNITION:
2020 - Presidential Commendation from the World Association for Photobiomodulation Therapy for service and leadership in the field
2021 - T.H. Maiman Award for excellence in medical laser research (named after Theodore H. Maiman, inventor of the first working laser in 1960)

ADDITIONAL ROLES AND CONTRIBUTIONS:
Co-founder of LumiThera Inc., which developed the first clinically proven treatment for dry age-related macular degeneration (AMD) using Photobiomodulation.